Please login to the form below

Not currently logged in
Email:
Password:

talimogene laherparepvec

This page shows the latest talimogene laherparepvec news and features for those working in and with pharma, biotech and healthcare.

Boehringer bolts on another immuno-oncology company

Boehringer bolts on another immuno-oncology company

Oncolytic virus-based therapies are consistent with and complement that strategy.”. The first oncolytic virus therapy to reach western markets was Amgen’s Imlygic (talimogene laherparepvec or T-Vec) which was

Latest news

More from news
Approximately 4 fully matching, plus 18 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Oncolytic viruses. An oncolytic virus is a virus that preferentially infects and kills cancer cells, and to date a handful of therapies – Amgen’s Imlygic (talimogene laherparepvec) in the US and

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics